OXYBUPROCAINE
Sponsors
Sintetica S.A., Dompe' Farmaceutici S.p.A.
Conditions
Atopic keratoconjunctivitis (AKC)Dry Eyeaged 0-17 years scheduled to undergo ocular exams with a need of ocular surface anesthesia.male/female outpatients
Phase 2
A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 2 Weeks of Follow-Up to Evaluate Safety and Efficacy of Two Different Dosages of Isocyclosporin A Eye Drop Solution Versus Vehicle in Adult Patients with Atopic Keratoconjunctivitis (AKC).
CompletedCTIS2023-508907-19-00
Start: 2024-05-10End: 2024-11-29Target: 69Updated: 2024-11-07
A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at two different Concentrations in patients with Dry Eye Disease (REDUCO study)
CompletedCTIS2023-507561-26-00
Start: 2024-05-17End: 2024-11-22Target: 126Updated: 2024-08-02
Phase 3
A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population.
WithdrawnCTIS2023-504477-21-00
Target: 74Updated: 2023-09-26
A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population.
CompletedCTIS2023-504477-21-01
Start: 2024-05-14End: 2025-03-13Target: 74Updated: 2024-12-13